100% fees at risk* 0% GLP-1 for weight loss trend guarantee 8% bodyweight reduction, with or without GLP-1 medications More than just marketing claims, validated weight loss results Years of nutrition-first care, medication management, and GLP-1 deprescription when clinically appropriate Learn about our approach Weight loss without drugs View our outcomes Sustained weight loss a year after GLP-1 deprescription See the results How it works Easy implementation via PBM integrations enables guardrails without rebate impact Navigate members to Virtas effective care via our PBM integrations and member communications Educate on the benefits of Nutrition Therapy and guide each member to the right care with or without GLP-1s Adapt nutrition and behavioral care to each member based on lifestyle, metabolism, and continuous health data Maximize success for those on GLP-1s with provider-led effective titration, side-effect support, and engagement monitoringno wasted spend on off-label prescriptions or ineffective anti-obesity medications
Nutrition, metabolism, and cardiovascular diseases: NMCD
Exendin-4 (Ex-4), another GLP-1RA that is homologous to commercially available exenatide, ameliorated IR in primary neurons through insulin receptor substrate-1 (IRS-1), AKT, and glycogen synthase kinase-3 (GSK-3) pathways
It appears safe to continue these medications before a procedure requiring anaesthesia or sedation, with minor precautions like abstaining from solid food for a day to minimize any potential risk of aspiration. Recent reports and studies suggest that taking GLP-1 medications is associated with slower digestion with a larger amount of food remaining in the stomach
Ongoing follow-up is an important part of care
